{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:26:03Z","timestamp":1783070763926,"version":"3.54.6"},"reference-count":13,"publisher":"Centers for Disease Control MMWR Office","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm6619a6","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T14:41:54Z","timestamp":1495118514000},"page":"509-513","source":"Crossref","is-referenced-by-count":92,"title":["Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine \u2014 Advisory Committee on Immunization Practices, 2016"],"prefix":"10.15585","volume":"66","author":[{"given":"Monica E.","family":"Patton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"MacNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1128\/MMBR.00056-12","article-title":"Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.","volume":"77","author":"McNeil","year":"2013","journal-title":"Microbiol Mol Biol Rev"},{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R2","doi-asserted-by":"publisher","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R3","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R4","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R5","unstructured":"Food and Drug Administration. Summary basis for regulatory action. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2016. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM496484.pdf"},{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R6","unstructured":"Food and Drug Administration. Trumenba U.S. package insert. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2014. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM421139.pdf"},{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/jpids\/piv039","article-title":"Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents.","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R8","unstructured":"Advisory Committee on Immunization Practices. Grading of recommendations, assessment, development, and evaluation (GRADE) for use of serogroup B meningococcal (MenB) vaccines in persons at increased risk for serogroup B meningococcal disease. Atlanta, GA: Advisory Committee on Immunization Practices; 2015. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/mening-serogroup-b.html#ref01"},{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R9","unstructured":"Advisory Committee on Immunization Practices. Grading of recommendations, assessment, development, and evaluation (GRADE) for use of serogroup B meningococcal (MenB) vaccines in persons at increased risk for serogroup B meningococcal disease. Atlanta, GA: Advisory Committee on Immunization Practices; 2014."},{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R10","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R11","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R12","unstructured":"Food and Drug Administration. Approaches to licensure of meningococcal vaccines for prevention of serogroup B invasive meningococcal disease. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/UCM248586.pdf"},{"key":"key-10.15585\/mmwr.mm6619a6-201705181030-R13","unstructured":"Food and Drug Administration. Bexsero U.S. package insert. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2015. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM431447.pdf"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T01:50:49Z","timestamp":1602121849000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/66\/wr\/mm6619a6.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":13,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2017,5,19]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm6619a6","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5,19]]},"published":{"date-parts":[[2017,5,19]]}}}